Saniona reports data from exploratory Phase IIa of Tesomet for Prader-Willi

Saniona AB (SSE:SANION) said data from an exploratory Phase IIa trial evaluating once-daily Tesomet tesofensine/metoprolol in patients with Prader-Willi syndrome showed that plasma concentrations of tesofensine were two to four times higher compared to previous studies in obese and diabetic patients

Read the full 416 word article

User Sign In